Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
Cancer Treatment Reviews
|
July 23, 2017
Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
Hadar Goldvaser, Domen Ribnikar, Rouhi Fazelzad, et al.
Journal of the International Neuropsychological Society : JINS
|
March 11, 2016
Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls
Christie Yao, Jill B Rich, Ian F Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
Eitan Amir, Bostjan Seruga, Joaquin Martinez-Lopez, et al.
The Lancet. Oncology
|
June 15, 2016
Under-reporting of harm in clinical trials
Bostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, et al.
Plos One
|
March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysis
Mustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Cancer Treatment Reviews
|
April 25, 2017
Efficacy, safety, tolerability and price of newly approved drugs in solid tumors
Tristan A Barnes, Eitan Amir, Arnoud J Templeton, et al.
Oncotarget
|
March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
Ariadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
Cancer Medicine
|
September 5, 2020
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors
Ramy R Saleh, Nicholas Meti, Domen Ribnikar, et al.
Breast Cancer Research and Treatment
|
February 22, 2016
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer
Alberto Ocaña, Javier Pérez-Peña, Laura Díez-González, et al.
The Lancet. Oncology
|
December 8, 2016
Relevance of randomised controlled trials in oncology
Ian F Tannock, Eitan Amir, Christopher M Booth, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
Cancer Treatment Reviews
|
July 23, 2017
Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer
Hadar Goldvaser, Domen Ribnikar, Rouhi Fazelzad, et al.
Journal of the International Neuropsychological Society : JINS
|
March 11, 2016
Pretreatment Differences in Intraindividual Variability in Reaction Time between Women Diagnosed with Breast Cancer and Healthy Controls
Christie Yao, Jill B Rich, Ian F Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs
Eitan Amir, Bostjan Seruga, Joaquin Martinez-Lopez, et al.
The Lancet. Oncology
|
June 15, 2016
Under-reporting of harm in clinical trials
Bostjan Seruga, Arnoud J Templeton, Francisco Emilio Vera Badillo, et al.
Plos One
|
March 4, 2014
Extended adjuvant tamoxifen for early breast cancer: a meta-analysis
Mustafa Al-Mubarak, Ariadna Tibau, Arnoud J Templeton, et al.
Cancer Treatment Reviews
|
April 25, 2017
Efficacy, safety, tolerability and price of newly approved drugs in solid tumors
Tristan A Barnes, Eitan Amir, Arnoud J Templeton, et al.
Oncotarget
|
March 31, 2018
Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
Ariadna Tibau, Geòrgia Anguera, Fernando Andrés-Pretel, et al.
Cancer Medicine
|
September 5, 2020
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors
Ramy R Saleh, Nicholas Meti, Domen Ribnikar, et al.
Breast Cancer Research and Treatment
|
February 22, 2016
Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer
Alberto Ocaña, Javier Pérez-Peña, Laura Díez-González, et al.
The Lancet. Oncology
|
December 8, 2016
Relevance of randomised controlled trials in oncology
Ian F Tannock, Eitan Amir, Christopher M Booth, et al.
Page
of 9